Stockwinners Market Radar for April 24, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:11 EDT Cathie Wood's ARK Investment bought 157K shares of Coinbase today

20:08 EDT Cathie Wood's ARK Investment bought 199K shares of Roblox today

18:50 EDT Southwest, TWU 550 reach tentative agreement for Meteorologists - Southwest Airlines and the Transport Workers Union Local 550 announced that they reached a Tentative Agreement for the airline's Meteorology Employees. This Tentative Agreement covers Southwest's Meteorologists. The TWU 550 will share details directly with its members about the agreement and the voting process.

18:31 EDT Southwest CEO: Demand environment is still very strong - In an interview on CNBC's Mad Money, Bob Jordan said demand is really strong in the leisure segment. "We have a 52 year history of being a terrific operator. One bad week won't change what Southwest Airlines stands for," he added. The company has things it needs to work on, but it's not behind on technology, he noted. The company plans to increase spending on technology in the coming years.

18:02 EDT CF Industries, NextEra Energy announce MOU for green hydrogen project - CF Industries (CF) and NextEra Energy (NEE) announced a memorandum of understanding for a joint venture to develop a zero-carbon-intensity hydrogen project at CF Industries' Verdigris Complex in Oklahoma. The proposed project was included in the funding application submitted to the U.S. Department of Energy this month by the HALO Hydrogen Hub, a three-state effort established by Arkansas, Louisiana and Oklahoma to compete for funding from the DOE's regional clean hydrogen hub program. CF Industries and NextEra Energy Resources anticipate that support for the project from the DOE program will be a key aspect of their evaluation process. A final investment decision has not been made for this project. The proposed project envisions a jointly owned 100-megawatt electrolysis plant at the Verdigris Complex that would be powered by a dedicated 450-MW renewable energy facility developed by NextEra Energy Resources. CF Industries would be the sole offtaker of 100% of the zero-carbon green hydrogen output from the site's electrolyzers. The green hydrogen would be used to produce up to 100,000 tons per year of zero-carbon green ammonia, which would be facilitated by debottlenecking Verdigris' ammonia plants. CF Industries expects the resulting green ammonia production to support the transition of American agriculture to low- and zero-carbon fertilizers, helping to remove up to 130,000 metric tons of carbon dioxide emissions from the agriculture supply chain each year.

17:56 EDT Virios jumps 23% after FDA feedback on proposed IMC-1 program for FM treatment - Virios Therapeutics jumps 23% or 14c per share to to 77c in late-day trading after announcing a program summary based on initial feedback from the U.S. Food & Drug Administration on its Phase 3 FM program proposal featuring its lead development candidate IMC-1. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted fibromyalgia disease symptoms. This feedback was provided following a guidance meeting between the Anesthesiology, Addiction Medicine and Pain Medicine division of FDA and the Company in The proposed Phase 3 program consists of four primary components: two adequate and well-controlled clinical studies, one of which would be a full factorial design with each of the individual components of IMC-1 as separate comparator arms, a long-term safety trial, and a pharmacokinetic/food effect study. Based on data from the recently completed FORTRESS Phase 2b trial, the Company proposed a Phase 3 development program targeting community-based FM patients, who have not participated in prior FM trials. Initial FDA feedback was that the Company's Phase 3 proposal is acceptable, subject to review of the final results from its recently completed chronic toxicology program. The Company will submit the final toxicology reports and associated data in May 2023.

17:29 EDT Huntington Ingalls awarded $115M Navy contract modification - Huntington Ingalls was awarded a $115M cost-plus-fixed-fee modification to a previously awarded contract for continued execution of the USS Columbus engineered overhaul. Work will be performed in Newport News, Virginia, and is expected to be completed by December 2023. Fiscal 2023 operations and maintenance funds in the amount of $115M will be obligated at the time of award and will expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:16 EDT Ellington Financial reports estimated book value per share $15.10 on March 31 - This estimate includes the effect of the previously announced monthly dividend of $15c per share of common stock, payable on April 25 to holders of record on March 31, with an ex-dividend date of March 30.

17:03 EDT Blue Foundry Bancorp announces share repurchase program - Blue Foundry Bancorp announced that it has adopted a program to repurchase up to 1,335,126 shares of its common stock, which is approximately 5% of its outstanding common stock commencing upon the completion of the company's existing stock repurchase program. This is the company's second stock repurchase program since completing its mutual-to-stock conversion and related stock offering in July 2021. On July 20, 2022, the company announced its first stock repurchase program which authorized the purchase of up to 2,852,250 shares. Under this previously announced program, through April 18, 2023, 2,723,979 shares of common stock have been repurchased at a cost of $30,240,939, or $11.10 per share. As of April 18, 2023, there are 128,271 shares remaining to be repurchased under this existing program.

17:00 EDT Cano Health opens three new medical centers in FL - Cano Health "announced it has opened three new medical centers throughout South Florida in an effort to reach more patients and introduce its services to a wider population in the market."

16:57 EDT Brink's names Laurent Borne chief experience officer - The Brink's Company announced that Laurent Borne will join the company as executive vice president and chief experience officer, effective May 15. Borne will lead global marketing efforts and have responsibility for the company's expanding digital retail solutions business. He will join the executive leadership team and report to president and chief executive officer Mark Eubanks. "We are laser-focused on providing a superior customer experience, and Laurent's track record in technology-led strategic transformation is a natural fit," said Eubanks. "His skills in value chain analysis, value proposition development, and voice of the customer integration will turbocharge our efforts to modernize the retail cash ecosystem."

16:51 EDT Vyant Bio announces voluntary Nasdaq delisting - Vyant Bio announced that on April 24, 2023 its Board of Directors determined it was appropriate to voluntarily delist its securities from The Nasdaq Capital Market. The company has initiated the delisting and filed a Form 25 with the Securities and Exchange Commission and the delisting is expected to become effective on or about May 14, 2023. The Company previously filed post-effective amendments to six Registration Statements on Form S-8, four Registration Statements on Form S-3 and two Registration Statements on Form S-1 previously filed by the Company with the SEC, in each case, to remove from registration any unsold securities previously registered thereon. Following the delisting of the Company's securities from Nasdaq, the Company intends to file a Form 15 with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended. The Company expects that the deregistration of such securities will become effective 90 days after the filing of the Form 25 with the SEC. The Board made the decision to pursue this strategy following its review and careful consideration of a number of factors, including, but not limited to, the expected reduction in operating expenses by eliminating SEC reporting costs, which would allow the Company to focus more resources on its continued pursuit and exploration of satisfactory strategic alternative transactions and/or execution of an orderly wind down of the Company, if necessary. The Board determined that deregistration is in the overall best interests of the Company and its stockholders.

16:46 EDT First Republic ends earnings call without taking questions - First Republic Bank ended its earnings conference call without taking questions from analysts. The shares are down 18% to $13.06 in after-hours trading post the results and conference call.

16:41 EDT Heliogen rejects unsolicited acquisition proposal from Continuum Renewables - Heliogen "announced that its Board of Directors rejected the unsolicited, non-binding proposal it received on April 13th from Continuum Renewables, Inc. to acquire all of the outstanding shares of common stock of Heliogen for cash consideration of $0.40 per share." The Board states that "the proposal would result in an implied equity value for Heliogen common stockholders that is materially below Heliogen's available liquidity. Additionally, the Board concluded that the proposal is subject to material contingencies, including CRI obtaining financing."

16:37 EDT Tenable Holdings falls 15% to $38.50 after Q1 results and guidance

16:36 EDT First Republic sinks 14% to below $14 after Q1 results, pursuit of options

16:33 EDT Net Power, Rice SPAC announce upsized PIPE commitment from Occidental - Net Power, LLC and Rice Acquisition Corp. II (RONI) announced an additional $275 million of PIPE commitments in connection with their proposed business combination. Occidental (OXY) has increased its commitment to the PIPE by $250 million, bringing its total investment to $350 million, while the Rice family has committed an additional $25 million to the PIPE, bringing their total investment to $125 million. The new commitments bring the expected gross proceeds of the business combination to $845 million for NET Power, consisting of approximately $345 million from RONI's trust account (assuming no redemptions), and approximately $500 million from the PIPE raised entirely at $10.00 per share of common stock. Assuming no RONI shareholders exercise their redemption rights, the combined company is expected to have a market capitalization in excess of $2.0 billion. Following this additional commitment, Occidental's ownership stake in the combined company will increase to approximately 39%, assuming no redemptions.

16:31 EDT LumiraDx receives noncompliance notification from Nasdaq - LumiraDx announced that it has received notification from Nasdaq that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the company's common shares on the Nasdaq Global Market was below $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5450 requires the common shares to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810 provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days.

16:27 EDT NBT Bancorp Q1 total deposits at March 31 were $9.68B, vs. $9.5B at year end - Total deposits at March 31 were $9.68B, compared to $9.5B. The increase in deposits was concentrated in time and money market accounts with seasonal municipal deposit inflows during the quarter. Loan to deposit ratio was 85.4% at March 31, 2023, compared to 85.8% at December 31.

16:26 EDT Whirlpool CEO says 'delivered significant sequential margin expansion' in Q1 - "In Q1, we delivered significant sequential margin expansion, in particular in North America. These results demonstrate our progress against our operational priorities and put us on track to deliver a solid 2023," said Marc Bitzer, chairman and CEO of Whirlpool Corporation. "At the same time, we are continuing to advance our ongoing portfolio transformation of investing in higher growth and higher margin businesses and remain confident in our ability to drive value over the long-term."

16:24 EDT 7 Acquisition Corporation to redeem public shares - 7 Acquisition Corporation announced that it will redeem all of its outstanding Class A ordinary shares, par value $0.0001 previously issued to the public, with such redemption anticipated to be effective as of the close of business on May 10, because the company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association. Net of taxes and dissolution expenses, the per-share redemption price for the Public Shares is expected to be approximately $10.48. In accordance with the terms of the related trust agreement, the company expects to retain $100,000 of the interest and dividend income from the Trust Account to pay dissolution expenses.

16:19 EDT First Republic reports Q1 deposits $104.5B, down 35.5% - Reports Q1 borrowings $106.7B, up $101.2B year-over-year.

16:15 EDT HomeStreet cuts quarterly dividend to 10c per share - HomeStreet announced that the company's Board of Directors approved a 10c per share quarterly dividend. The dividend is payable on May 24, 2023 to shareholders of record at the close of business on May 10, 2023. "In light of the lower level of earnings in the first quarter of 2023 and the highly uncertain interest rate and economic environment over the near term, in an abundance of caution, the Board of Directors determined that it would be prudent to reduce our dividend this quarter to 10c per share," said Mark K. Mason, HomeStreet's Chairman of the Board, President, and CEO.

16:15 EDT TrueBlue backs FY23 CapEx view $36M-$40M - Sees FY23 gross margin down 20 basis points to up 40 basis points, previous view down 30 to up 30.

16:13 EDT Trinity Capital provides $40M growth capital to Convergent Dental - Trinity Capital announced a $40M facility to support the growth of Convergent Dental, the power behind Solea, the world's first computer-aided all-tissue CO2 dental laser. $20M was drawn under the facility, and Convergent Dental has the option to draw an additional $20M, subject to the conditions under the agreement.

16:11 EDT Canadian National, Union Pacific, GMXT announce new intermodal service - CN (CNI), Union Pacific Railroad UNP) and GMXT proudly announced today the creation of Falcon Premium intermodal service, a best-in-class Mexico-US-Canada service with a seamless rail connection in Chicago, Illinois. It will directly connect all CN origin points within Canada and Detroit, Michigan to GMXT terminals in Mexico: Monterrey, Nuevo Leon, and Silao, Guanajuato. This service will directly benefit intermodal customers shipping automotive parts, food, FAK, home appliances, and temperature-controlled products. Falcon Premium service will be the fastest, most reliable intermodal rail service between Canada and Mexico by combining the unique benefits of each partner. The seamless service will leverage GMXT's best-in-class transit times between Silao, Guanajuato, and Eagle Pass, Texas; Union Pacific's superior route from Texas to Chicago and CN's best-in-class service connecting Chicago to all points in Canada through the unique EJ&E Chicago bypass. This new and innovative service allows the maximization of lading weights between Mexico/Canada for greater efficiency for customers. Falcon Premium intermodal service will also contribute to lower greenhouse gas emissions through reduced rail miles and significant truck-to-rail conversion.

16:08 EDT Canadian National, Union Pacific announce creation of Mexico-US-Canada service - Canadian National (CNI) Union Pacific Railroad (UNP) and GMXT announced the creation of Falcon Premium intermodal service, a Mexico-US-Canada service with a rail connection in Chicago, Illinois. It will directly connect all CN origin points within Canada and Detroit, Michigan to GMXT terminals in Mexico: Monterrey, Nuevo Leon, and Silao, Guanajuato. This service will directly benefit intermodal customers shipping automotive parts, food, FAK, home appliances and temperature-controlled products.

16:07 EDT Cleveland-Cliffs cuts FY23 CapEx view to $675M-$725M from $700M-$750M

16:04 EDT Bank OZK announces return of John Carter as Chief Credit Officer - Bank OZK announced that John Carter has returned as Chief Credit Officer. In this capacity, he will be responsible for oversight of the bank's credit, loan operations, special assets and mortgage lending functions. In addition, Carter will participate in the development of corporate strategy for lending practices and policies. "We are so pleased to welcome John back to the Bank OZK team to once again lead our credit management practices," stated George Gleason, Chairman and Chief Executive Officer. "He has a proven record, having risen through our ranks during his previous tenure with the bank where John was instrumental in the expansion of our community banking footprint throughout the southeast. Given his deep understanding of our business and corporate culture, I know John will hit the ground running to deliver value to our team and clients." "I am thrilled to return to Bank OZK as Chief Credit Officer where I spent the formative years of my banking career," said Carter. "During my previous eleven-year tenure, I witnessed firsthand the drive, discipline and commitment to excellence that resulted in Bank OZK's strong asset quality, impressive growth and its repeated recognition as one of the top banks in the country. I look forward to collaborating with the bank's dynamic leadership team and helping our clients achieve their financial goals."

16:02 EDT Celyad receives Nasdaq initial notification on ADS bid price - Celyad Oncology received a letter on April 19th, 2023 from The Nasdaq Stock Market informing the company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares was below $1.00 for a period of 30 consecutive business days and that the company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Bid Price Notice has no immediate effect on the listing of the company's ADSs on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, or until October 16, 2023, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the company's ADSs must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date.

14:31 EDT Bank of Hawaii CFO sees Q2 margin decline 'similar' to what was seen in Q1 - Asked on the bank's earnings call about margin expectations, Bank of Hawaii CFO Dean Shigemura said: "Right now, we're expecting the Fed to increase rates next week and then possibly another one, but pause from that point on. But when you look at that compared to what the futures are expecting, we're actually looking at a higher for longer kind of rate environment and then version carrying through to sort of the middle of next year. So based on that, we're looking at the margin coming down in the second quarter and then really bottoming up towards the end of this year before increasing into the next year, assuming the rates do come down on the short end towards the tail end of 2024." Asked a follow-up regarding where he thinks it will bottom, Shigemura replied: "We're looking at right now, at least in the second quarter, a similar decline as we saw in the first quarter. And then from there, it will start to grow."

13:44 EDT Tesla raises FY23 CapEx view to $7B-$9B from $6B-8B - In a regulatory filing, Tesla said that it raised its capital expenditures view for 2023 to $7B-$9B from $6B-$8B. "Our capital expenditures are typically difficult to project beyond the short-term given the number and breadth of our core projects at any given time, and may further be impacted by uncertainties in future global market conditions," the car maker said. "We are simultaneously ramping new products, ramping manufacturing facilities on three continents, piloting the development and manufacture of new battery cell technologies and investing in autonomy and other artificial intelligence enabled products, and the pace of our capital spend may vary depending on overall priority among projects, the pace at which we meet milestones, production adjustments to and among our various products, increased capital efficiencies and the addition of new projects. Owing and subject to the foregoing as well as the pipeline of announced projects under development, all other continuing infrastructure growth and varying levels of inflation, we currently expect our capital expenditures to be between $7.00 to $9.00 billion in 2023 and in each of the following two fiscal years. Our business has recently been consistently generating cash flow from operations in excess of our level of capital spend, and with better working capital management resulting in shorter days sales outstanding than days payable outstanding, our sales growth is also facilitating positive cash generation. We have and will continue to utilize such cash flows, among other things, to do more vertical integration, expand our product roadmap and provide financing options to our customers. On the other hand, we are likely to see heightened levels of capital expenditures during certain periods depending on the specific pace of our capital-intensive projects and rising material prices and increasing supply chain and labor expenses resulting from changes in global trade conditions and labor availability associated with the COVID-19 pandemic. Overall, we expect our ability to be self-funding to continue as long as macroeconomic factors support current trends in our sales."

13:33 EDT Imax announces pact with Major Cineplex for up to ten Imax with Laser systems - Imax and Major Cineplex announced plans to further expand their longstanding partnership with an agreement for up to ten Imax with Laser systems. The new agreement will add an additional five new - two firm and three conditional - Imax with Laser systems across Thailand. The deal also includes four upgrades to key locations in the country by 2025, including locations in Bangkok, Nonthaburi and Chiang Mai, and one upgraded location in Cambodia, Imax stated at the annual CinemaCon 2023 exhibition conference in Las Vegas.

13:29 EDT Appeals court upholds ruling for Apple on App Store policies in fight with Epic - The U.S. Court of Appeals for the Ninth Circuit affirmed in part and reversed in part the district court's judgment, after a bench trial, against Epic Games, Inc., on its Sherman Act claims for restraint of trade, tying, and monopoly maintenance against Apple, Inc.; in favor of Epic on its claim under California's Unfair Competition Law; against Epic on Apple's claim for breach of contract; and against Apple on its claim for attorney fees. "The panel affirmed except for the district court's ruling respecting attorney fees, where it reversed and remanded for further proceedings," a ruling filed April 24 that was published to the court's website stated. Investors in Epic include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY). Reference Link

13:04 EDT Zoom up 4% after FT says Microsoft may stop bundling Teams with Office - Shares of Zoom Video (ZM) are up about 4% in afternoon trading after Financial Times reported that Microsoft (MSFT) has offered to stop forcing customers of its Office software to also have its Teams video conferencing and messaging app automatically installed on their devices to prevent an official antitrust probe by EU regulators.

12:21 EDT Carrier down 5% to $42.80 after WSJ report of close Viessmann deal

12:02 EDT Accenture, Google Cloud expand partnership for cybersecurity - Accenture (ACN) and Google Cloud (GOOG, GOOGL) announced an expansion of their global partnership to help businesses better protect critical assets and strengthen security against persistent cyber threats. Together, they are providing the technology, trusted infrastructure, and security expertise organizations need to build resilient security programs and maintain confidence in their readiness.

12:00 EDT Eventbrite falls -8.4% - Eventbrite is down -8.4%, or -68c to $7.32.

12:00 EDT Clearwater Paper rises 12.5% - Clearwater Paper is up 12.5%, or $4.07 to $36.74.

12:00 EDT Getty Images rises 40.1% - Getty Images is up 40.1%, or $2.03 to $7.09.

11:58 EDT IN8bio treatment of malignant glioma granted FDA orphan status - IN8bio's treatment of malignant glioma was granted orphan designation from the FDA, according to a post to the agency's website. Reference Link

11:41 EDT Fox News says 'agreed to part ways' with Tucker Carlson - Fox News Media and Tucker Carlson have "agreed to part ways," the company announced. "We thank him for his service to the network as a host and prior to that as a contributor," Fox News added in its statement. "Carlson's last program was Friday April 21st. Fox News Tonight will air live at 8 PM/ET starting this evening as an interim show helmed by rotating Fox News personalities until a new host is named," Fox said. Reference Link

11:25 EDT Blue Apron, WW team up for 'limited time offer' - Blue Apron (APRN) and WW (WW) are teaming up for what they call a "limited time offer." Blue Apron said: "A balanced diet can be delicious-and it can be made simpler. We've partnered with WW (formerly Weight Watchers) to provide chef-designed recipes that are WW Recommended and made with quality ingredients that don't sacrifice flavor." New meal plan subscribers get $110 off Blue Apron and and their first WW month for only $10, and the deal is available now through June 30. Reference Link

11:00 EDT Jupiter Wellness Acquisition Corp trading halted, volatility trading pause

10:31 EDT Tellurian's driftwood pipeline project receives FERC certificate - Tellurian announced that the U.S. Federal Energy Regulatory Commission, or FERC, issued the certificate on April 21, 2023 granting authorization for Driftwood Pipeline's Line 200 and Line 300, an approximate $1.4B natural gas transmission project proposed to be located in Beauregard and Calcasieu Parishes, Louisiana. The pipelines will have the ability to supply up to five and one-half billion cubic feet of natural gas daily with virtually no emissions due to the implementation of electric-powered Integrated Compressor Line technology from Baker Hughes.

10:02 EDT White Diamond says McDonald's not a Presto customer as company removes logo - Presto Automation (PRST) went up 36% on Friday but over the weekend, it removed the McDonald's (MCD) logo from customer section of its website, White Diamond Research says. "There have been rumors that Presto has a deal with McDonald's," White Diamond adds, which would be a big deal because the latter has been in the news lately for being the first fast food restaurant with a fully automated drive-thru. White Diamond Research believes the logo got removed because "the reality is McDonald's isn't a customer of PRST in any way, and expects the stock "to plummet to previous levels of around $1.50 once word gets out." Reference Link

10:00 EDT TPG RE Finance falls -4.9% - TPG RE Finance is down -4.9%, or -36c to $7.01.

10:00 EDT C3.ai falls -6.6% - C3.ai is down -6.6%, or -$1.32 to $18.74.

10:00 EDT Philips rises 13.8% - Philips is up 13.8%, or $2.63 to $21.66.

09:47 EDT Costamare falls -4.0% - Costamare is down -4.0%, or -38c to $9.12.

09:47 EDT C3.ai falls -9.5% - C3.ai is down -9.5%, or -$1.91 to $18.15.

09:47 EDT Philips rises 14.1% - Philips is up 14.1%, or $2.69 to $21.71.

09:38 EDT Cerevel holder Perceptive in talks about 'potential strategic transaction' - In a regulatory filing on Friday, Perceptive Advisors disclosed a 6.4% stake in Cerevel Therapeutics and stated: "Perceptive Advisors is currently engaging in preliminary discussions with the [company] and certain third parties about a potential strategic transaction, although there is no assurance that any transaction will materialize."

09:32 EDT MoneyGram appoints Seth Ross as CDO - MoneyGram International announced the appointment of Seth Ross as Chief Digital Officer. In this role, Ross will lead the Company's direct-to-consumer business and global digital strategy. He will report directly to Alex Holmes, MoneyGram Chairman and CEO, and will sit on the Executive Leadership Team. Ross brings a wealth of knowledge and experience to MoneyGram, most recently serving as General Manager, Dayforce Wallet and Consumer Services at Ceridian.

09:15 EDT T-Mobile extends collaboration with VA, will be primary wireless provider - The U.S. Department of Veterans Affairs, or VA, selected T-Mobile as its primary wireless provider. This extends T-Mobile's collaboration with the VA another nine years. As part of the agreement, T-Mobile will deploy an estimated 50,000 wireless lines for VA healthcare professionals - including doctors, nurses, social workers and crisis hotline staff - so they can stay connected to the millions of veterans they serve. The contract also includes T-Mobile 5G Internet for broadband at the VA's Community-Based Outpatient Clinics, or CBOCs, which provide primary and mental health care in rural areas.

09:12 EDT Citius Pharmaceuticals provides update on Mino-Lok Phase 3 trial - Citius Pharmaceuticals has advanced its clinical trial for Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Of the 92 events required to complete the trial, the company estimates that 85 events have been achieved to date. The trial has enrolled 190 patients, of which 16 patients are in active treatment or pending study completion data review, which may result in additional events. The multi-center Mino-Lok Phase 3 trial continues to recruit patients at 35 clinical trial sites in the U.S. and India. The primary endpoint for this study is the time to a catheter failure event between randomization and TOC in the Intent-to-Treat Population. Additional secondary outcome measures include overall success, microbiological eradication, and clinical cure, among others.

09:12 EDT Lexaria Bioscience awards CRO contract to InClin - Lexaria Bioscience announces it has awarded the contract for clinical research organization services for its expected upcoming Food and Drug Administration-registered, U.S. Phase 1b Investigational New Drug hypertension study HYPER-H23-1 with its patented DehydraTECH-powered cannabidiol to California-based InClin, Inc. Study HYPER-H23-1 is entitled 'A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension' . The primary objective of the study will be to evaluate safety and tolerability in 120 hypertensive patients, and secondary objectives will include efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing. InClin is about to begin study start-up and preparatory activities to enable Lexaria to "hit the ground running" with patient dosing as soon as possible after the expected FDA IND filing and review is completed. Lexaria anticipates filing the IND this summer with hoped-for FDA authorization within about 60 days, resulting in the Phase 1(b) trial aggressively targeting commencement of patient dosing as early as October 2023. The study start-up services to be provided by InClin include but are not limited to: clinical site evaluation and selection, personnel and site training, project management, clinical database design and management, quality assurance support, medical writing, study documentation creation, biostatistics and programming, support vendor coordination, Independent Review Board submissions and more.

09:09 EDT Assertio Holdings provides educational grant for new LGS foundation kits - Assertio announced that it is providing educational grant funding for the Lennox-Gastaut Syndrome, LGS, Foundation's new About LGS Treatments Kits for families coping with LGS. Assertio markets SYMPAZAN oral film CIV, approved by the U.S. Food and Drug Administration, FDA, for the adjunctive treatment of seizures associated with LGS in patients aged two years of age or older. Assertio announced in December that it provided a $100,000 educational grant to the LGS Foundation. "Assertio is proud to support the LGS community," said Dan Peisert, President and Chief Executive Officer of Assertio. "Our focus is on working with the LGS Foundation to help raise awareness of LGS and to support development of educational materials that can benefit their community."

09:07 EDT Lenovo, Critical Start form partnership - Critical Start, a provider of Managed Detection and Response cybersecurity solutions, announced a new partnership with Lenovo aimed at enhancing security within the company's Digital Workplace Solutions Group. Under the terms of the partnership, Lenovo will utilize Critical Start's MDR services to help their customers reduce cybersecurity risk associated with security breaches by enhancing their technology investments with cutting-edge Managed Detection and Response capabilities.

09:05 EDT Clover Health enters agreement to settle securities class action litigation - Clover Health Investments announced that the Company has reached an agreement to resolve the securities class action captioned Bond v. Clover Health Investments, Corp. et al., Case No. 3:21-CV-00096, which was filed in the wake of its de-SPAC transaction. The proposed settlement contains no admission of liability or wrongdoing by any of the defendants, including the Company, and is subject to definitive documentation and final court approval. On April 21, 2023, the parties to the securities class action entered into a memorandum of understanding providing for the settlement of the class action. Subject to negotiation of definitive documentation and final court approval, the class will receive $22 million dollars, the defendants will receive customary releases, and the litigation will be concluded. The Company will use insurance proceeds totaling $19.5 million that have been advanced or have been committed to be advanced by the Company's insurers to fund the settlement. The Company expects to pay $2.5 million of out-of-pocket costs to fund the settlement. The Company previously filed a lawsuit in Delaware state court against certain of its insurers for full payment of its liabilities related to this securities litigation. The Company intends to continue to pursue that litigation against the insurance carrier defendants to seek to recover additional funds, and intends to oppose any efforts by the carrier defendants to recoup any insurance proceeds that they have advanced or committed to advance to date. This settlement is subject to definitive documentation and final court approval. The defendants have denied all wrongdoing and have entered into this settlement to avoid the burden, expense, and distraction of ongoing litigation. Further information on the settlement will be available upon the filing of the formal notice of settlement to class members, and the above descriptions of the settlement is qualified entirely by the definitive settlement papers and corresponding notice.

09:03 EDT Sprout Social announces launch of The Arboretum - Sprout Social announced the launch of The Arboretum, a community platform for social and marketing professionals to connect with peers, learn new skills, and exchange actionable advice. The community is open to all marketers at no cost. Members have access to networking and educational opportunities, and the ability to connect with like-minded peers-from practitioners to C-suite executives. "Mentorship has been one of the most valuable resources in advancing my career, and the impact of having access to a community of industry experts cannot be understated," said Jamie Gilpin, CMO, Sprout Social. "Our collective knowledge is a powerful asset that will help marketers across the globe inform org-wide business strategies while leveling up their skills and careers. We're excited to see how the community will turn shared insights into action."

09:02 EDT LPL Financial: Dustin Mac Brown joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Dustin Mac Brown CFP, AAMS has joined LPL Financials' broker-dealer, RIA and custodial platforms. He reported having served approximately $190 million in advisory, brokerage and retirement plan assets, and joins LPL from Cetera Advisors.

08:48 EDT Hydrexia expands partnership with Howden to include Chart Industries solutions - Hydrexia and Chart Industries have expanded the existing cooperation agreement with Howden to include Chart's hydrogen solution offerings focused on streamlining mobility applications, specifically hydrogen refueling stations. Under the expanded agreement, Chart, Howden and Hydrexia will combine their expertise to deliver complete refueling stations solutions with a modularization concept bringing cost and lead-time efficiencies for their customers in Australia, New Zealand, and Southeast Asia.

08:45 EDT Snail announces ARK: Survival Ascended to release in August 2023 - Snail announced ARK: Survival Ascended, ASA, the next-generation remaster of the beloved ARK: Survival Evolved, harnessing the power of Unreal Engine 5, is expected to release on Xbox Series S/X, PC, and PlayStation 5 in August 2023. ASA is expected to be available as a standalone package on all platforms at $59.99. Upon launch, ASA players will gain access to The Island, Survival of the Fittest and Scorched Earth. The other DLCs will be added over time. Moreover, a new canonical-story expansion pack for ASA is expected to be available in Q4 2023, introducing four new creatures and more details to be revealed later this year. Jim Tsai, Chief Executive Officer of Snail, commented, "We are excited to bring ASA to our loyal players and new audiences alike. Leveraging the power of UE5, we aim to elevate the iconic ARK gaming experience to new heights, providing enhanced visuals, gameplay, and features that will engage the community for years to come."

08:44 EDT ETFS Capital files preliminary proxy statement to WisdomTree - ETFS Capital, the largest combined owner of common stock of WisdomTree, with aggregate ownership of approximately 10.2% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18.3% of the Company's outstanding Common Stock on an as-converted basis, announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission for the election of three highly-qualified individuals to the Board of Directors of WisdomTree at the Company's 2023 annual meeting of stockholders and issued an open letter to fellow WisdomTree stockholders. "Given such high stakes, we are deeply concerned with the Company's inability to deliver stockholder value and the failure of its long-tenured directors - Frank Salerno and Win Neuger - to provide necessary Board oversight.... We encourage stockholders to consider the following facts:Turnover of "New" Directors: Among the most alarming of recent developments at the Company is the fact that two recently appointed female directors have left the Board within the last ten months... Even more egregiously, the Company has decided that Deborah Fuhr, who joined the Board in May 2022 as part of our cooperation agreement with WisdomTree, will not be nominated to stand for election at the Annual Meeting.... We believe stockholders should question the Board's poor track record and lackluster support of highly qualified female directors and whether there has been a deliberate effort to stifle such voices. Questionable Director Replacement: Even more suspicious than Ms. Fuhr's hasty removal and the unexplained loss of credible expertise in the ETF space is the Board's selection of a replacement candidate, Shamla Naidoo.. Considering Ms. Naidoo's experience is primarily in cybersecurity and IT, an expertise typically covered by the Chief Information Security Officer and the fact she has zero ETF or related industry experience, we question the Board's rationale for adding her as the newest director candidate... Control of Key Committees by Long-Tenured Directors: According to WisdomTree's preliminary proxy statement, "the Board proactively added five new independent and diverse directors" since 2021. Interestingly, none of the new directors have been awarded any leadership positions on key committees... Pay-for-Performance Disparity: Frank Salerno has served as a director since 2005 - almost 18 years. He has been the Chair of the Board and the Chair of the Compensation Committee since 2018. Over this period, the Founder/CEO led management team has destroyed $921 million in market cap3. Instead of holding the CEO accountable, the Compensation Committee under Mr. Salerno's leadership awarded the CEO more than $21 million in compensation... We firmly believe that with the right Board in place, WisdomTree can be a best-in-class company in its industry and generate significant value for all stockholders. It is clear to us that the Board needs true change - not by way of individuals cherry-picked by the long-tenured directors - to trigger the actions urgently required to address the dismal performance of the Company. We recently sought to engage with the Board in a constructive dialogue on this matter to reach a mutually agreeable resolution to avoid a proxy contest in 2023, but the Company has repeatedly refused to have any meaningful dialogue or make any offer or proposal that might facilitate any form of settlement."

08:43 EDT Coca-Cola sees 'fair amount of uncertainty' around operating environment - Comments taken from Q1 earnings conference call.

08:41 EDT Siyata Mobile adds Two Way Direct as distributor for SD7 solution - Siyata Mobile announces Two Way Direct is now a distributor of Siyata's mission-critical PoC SD7 solution and its broad range of accessories.

08:41 EDT Smart Powerr receives notice of filing delinquency from NASDAQ - Smart Powerr announced that it received written notification from Listing Qualifications Department of the Nasdaq Stock Market that, as a result of not having timely filed its annual report on Form 10-K for the year ended December 31, 2022, the Company is no longer in compliance with the Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission. Under the Nasdaq Listing Rule 5810(c)(2)(F)(i), the Company is required to submit its plan to regain compliance (the "Compliance Plan") no later than June 20, 2023. If the plan is accepted by Nasdaq, CREG can be granted up to 180 calendar days from the Form 10-K's due date, or until October 16, 2023, to regain compliance.

08:40 EDT Salix partners with Colorectal Cancer Alliance on community screening program - Bausch Health Companies and its gastroenterology business, Salix Pharmaceuticals, announced a partnership with the Colorectal Cancer Alliance to increase awareness and access to preventative colorectal screenings in medically underserved communities. This May, the Alliance is launching a colorectal cancer screening and prevention initiative in Philadelphia with a focus on the communities facing the greatest disparities in health outcomes. In support of the Alliance's efforts to improve access to these screenings, Salix will donate its prescription bowel preparation product to individuals who require a colonoscopy. Colonoscopies are a critical tool in the early detection of colorectal cancer. Research shows colorectal cancer can have a 90% survival rate if caught early.

08:38 EDT Hesai obtains ISO 26262 ASIL B Safety Standard for QT128 lidar sensor - Hesai has obtained ISO 26262 ASIL B - Performance Level D Functional Safety Standard for the short-range lidar QT128, which is designed for blind spot coverage on autonomous taxis, trucks, and industrial applications. Obtaining this certificate means that Hesai has a high-quality product development process system and can provide safer and more reliable automotive-grade lidar products for the world's top automakers. It also means that Pandar128 and QT128, automotive-grade lidar solutions for the L4 market, can support vehicles to meet the relevant requirements of ASIL D, the highest functional safety level for autonomous driving. Lidar certified by functional safety can detect potential risks in electrical/electronic systems, sending an alarm to the intelligent driving system and initiating protection.

08:37 EDT Lixte reports GEIS completed first site initiation visit in prep of ASTS trial - LIXTE Biotechnology announced that the Spanish Sarcoma Research Group, GEIS, completed its first site initiation visit in preparation for the advanced soft tissue sarcoma, ASTS, clinical trial at Fundacion Jimenez Diaz University Hospital. Fundacion Jimenez Diaz University Hospital is the home base of Dr. Javier Martin-Broto, Coordinating Investigator of the clinical trial, GEIS Co-Founder, and an internationally recognized expert in sarcoma research and therapy. Three additional GEIS-associated cancer research centers, located in Valencia, Barcelona, and Madrid, Spain, are expected to be activated in the near-term, with Phase 1b patient accrual planned to begin by mid-May 2023. John Kovach, MD, Founder and CEO of LIXTE, said, "We are very pleased to finally have an opportunity to test whether LB-100 improves the treatment of ASTS. GEIS has been very patient, having had to wait several months for various regulatory approvals to introduce LB-100 into a European clinical trial program. The fact that this trial design is still relevant attests to the slow pace of finding better treatments for this disease."

08:35 EDT Veon appoints Jagan Mohan as group head of internal audit - VEON announces it has appointed Jagan Mohan, its current Group Director of Internal Audit, as the Group Head of Internal Audit, effective 1st May. This complements the Group Chief Financial Officer transition where Joop Brakenhoff, currently VEON's current Chief Internal Audit and Ethics & Compliance Officer, will assume the role of Group Chief Financial Officer also on 1st May 2023. In this new role, Jagan Mohan will report functionally to Michiel Soeting, the Chairman of VEON's Audit and Risk Committee, and operationally to Kaan Terzioglu, our Group CEO.

08:34 EDT NN, Inc. opens plant in Sao Joao da Boa Vista, Sao Paulo, Brazil - NN has opened a state-of-the-art 50,000+ square foot facility in Sao Joao da Boa Vista, Sao Paulo, Brazil. NN employs approximately 3500 associates globally, including approximately 600 in Sao Joao da Boa Vista. This new facility, the third on the Sao Joao da Boa Vista campus, will provide jobs for an additional 200 employees, making NN a top employer in the area. "The Company has operated in Brazil since 1998, and our employees have been a critical part of our success. This plant strengthens our commitment to provide precision manufacturing components at scale to our customers everywhere," said Jesus Garcia, General Manager of the facility. "NN is proud to create value for our customers while supporting our local associates and community." NN, which operates under the Autocam brand in Brazil, is transferring some operations from Boituva, Sao Paulo to the existing Sao Joao da Boa Vista location. The move takes advantage of incentives offered by the municipal government of Sao Joao da Boa Vista. Consolidating onto one campus optimizes operations in Brazil while providing needed room for expansion.

08:34 EDT Gogo to expand 5G footprint into Canada - Gogo Business Aviation announced it will expand its Gogo 5G network into Canada, providing additional coverage to business aviation operators in North America. Following the successful critical design review of the 5G chip earlier this year, Gogo 5G service is expected to launch commercially in the fourth quarter of 2023, with completion of the network expansion into Canada in 2024.

08:34 EDT Itafos announces record ofdecision for Husky 1/North Dry Ridge Project - Itafos announced the Record of Decision for the Husky 1 / North Dry Ridge mine development project. The Company anticipates breaking ground this summer. The H1 / NDR project will be internally funded and comprises primarily of infrastructure and mine development. Mineral resources from H1 / NDR are expected in 2026, providing an uninterrupted supply as the Rasmussen Valley Mine reaches the end of its useful life. "The Itafos team has taken several steps to unlock stakeholder value including reducing leverage, extending debt maturities and establishing an industry leading safety culture," said David Delaney, Chief Executive Officer. He added "the Record of Decision is another important step toward achieving our strategic goal of extending Conda's mine life with H1 / NDR. This supports over five hundred jobs in southeast Idaho, where we mine and manufacture phosphate ore and fertilizers in support of North American agriculture. Itafos, and the Conda community, would like to thank the Bureau of Land Management, the U.S. Forest Service and all the other regulatory agencies for their diligent and collaborative work on this project. The permit will allow us to work to continue to serve the North American fertilizer market through 2037 with potential to further extend the resource life through leases and third-party arrangements. Itafos is excited about this next chapter and will begin breaking ground this summer."

08:32 EDT Trillium Capital proposes to acquire Getty Images for $10.00 per share in cash - Trillium Capital announced a non-binding proposal to acquire Getty Images Holding for $10 per share in cash. "The principals of Trillium Capital LLC own hundreds of thousands of shares of common stock and common stock equivalents of Getty. Our non-binding proposal is contingent upon a number of things. These include immediate engagement by the Board of Directors of Getty, completion of satisfactory due diligence, obtaining satisfactory financing arrangements, entering a satisfactory purchase & sale contract, filing and completion of all regulatory matters related to our non-binding proposal and approval of shareholders, to name a few things. We may require other things to complete our non-binding proposal that we will determine at our sole discretion. We may consider permitting the holders of the large block of shares of Getty who own over 80% of the shares outstanding to roll some or all their shares into our transaction. The principals of Trillium Capital will hold their shares of common stock of the company if our non-binding proposal reaches a favorable conclusion. Should our non-binding proposal be accepted, and we close the proposed transaction, we would expect that our Managing Partner will join the Board of Getty and become its Chairman. He has decades of experience in corporate governance, strategy, finance, technology and building scale companies. We urge the Board to enter a non-disclosure agreement with us and allow us to commence due diligence as soon as possible. We may withdraw our non-binding proposal at any time without notice. We believe that our non-binding proposal might create substantial value for the shareholders of Getty."

08:31 EDT Inspired Entertainment expands partnership with Fanduel for iGaming content - Inspired Entertainment has partnered with FanDuel, a subsidiary of Flutter Entertainment, to launch premium iGaming content in Michigan. FanDuel will launch with four of Inspired's titles, as well as Big Spin Bonus, which is Inspired's top performer in the North American market and has proven to be extremely popular with players.

08:31 EDT LogicMark launches medical alert devices in Amazon's U.S. store - LogicMark (LGMK) announced that some of the medical alert devices in its portfolio and accessories are now available for purchase in Amazon's (AMZN) U.S. store. "Our mission at LogicMark is to let people lead a life with dignity and independence, and in order to do this in a bigger way we need to meet our customers where they are and give them more access to our products," said LogicMark CEO, Chia-Lin Simmons. "Offering our products in the Amazon store is a natural next step and extension of our distribution channels. We're proud and excited to be able to reach more customers and bring peace of mind to the one in four millennials, and the more than half of genX 'sandwich generation' caretakers in the U.S."

08:29 EDT GRI Bio announces board of director appointments - GRI Bio announced the appointments of David Szekeres, Roelof Rongen, MSE, MBA, and Camilla Simpson, M.Sc. to the Company's Board of Directors. Szekeres will serve as Chairman of the Board. As previously announced, GRI Bio will commence trading on The Nasdaq Capital Market under the ticker symbol "GRI", effective today, April 24, 2023, as a result of its recently completed its merger with Vallon Pharmaceuticals (VLON). David Szekeres has more than two decades of experience in the global life sciences industry as a finance and business development executive, deal maker, legal counsel and board member. Szekeres joined Heron Therapeutics (HRTX)as Chief Operating Officer and Head of Finance. Rongen currently serves as Chief Executive Officer of gene-therapy company, Adolore BioTherapeutics, Managing Partner of AsteRx Pharma Consulting and Founder/Chief Executive Officer of Innovative Molecules. Camilla Simpson serves as Chief Executive Officer of Zehna Therapeutics, an early-stage biotech and spin-out from the Cleveland Clinic.

08:27 EDT Sportradar announces nomination of two new directors - Sportradar Group (SRAD) announced that executives, Rajani Ramanathan and William Kurtz, will stand for election as independent members of its Board of Directors at the company's annual general meeting of shareholders, on May 16, 2023 in St. Gallen, Switzerland. In addition to Ramanathan and Kurtz, the candidates for the seats include seven incumbent directors advanced by the board. Ramanathan currently serves as an advisor and director to several public and private technology companies in the AI, VR, Blockchain, and connected technology space. Currently, Ramanathan is a member of the board of directors of ESI Group. Kurtz has over 30 years of experience as a chief financial officer and chief operating officer in several high-growth technology equipment and software companies and likewise sits on several corporate boards. Kurtz currently sits on the board of directors of Aterian (ATER). Additionally, Chuck Robel, who has served on the board since September 2020, will retire from the company's board this year and will not stand for re-election at the annual general meeting.

08:25 EDT Aevitas announces asset purchase agreement with 4D Molecular - Aevitas Therapeutics, a Fortress Biotech (FBIO) subsidiary company, and 4D Molecular Therapeutics (FDMT), announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas' proprietary rights to its short-form human complement factor H asset for the treatment of complement-mediated diseases. Under the terms of the agreement, 4DMT will make cash payments to Aevitas totaling up to ~$140 million in potential late-stage development, regulatory and sales milestones. A range of single-digit royalties on net sales are also payable. The aforementioned payments are payable solely to Aevitas, and 4DMT will be responsible for license payment obligations to University of Pennsylvania, where the sCFH technology was co-invented and co-developed by Dr. Wenchao Song, a Professor of Pharmacology at the Perelman School of Medicine. Aevitas' transgene encoding sCFH, a shortened and optimized form of a natural inhibitor of the inflammatory complement pathway, will be combined with 4DMT's proprietary retinotropic R100 vector to form product candidate 4D-175 for treatment of GA secondary to age-related macular degeneration.

08:24 EDT Agrify receives Nasdaq notification of non-compliance with listing rule - Agrify Corporation announced that on April 18, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying Agrify that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, with the Securities and Exchange Commission. This notification has no immediate effect on the listing of Agrify's common stock on the Nasdaq. However, if Agrify fails to timely regain compliance with the Nasdaq Listing Rule, Agrify's common stock will be subject to delisting from Nasdaq.

08:21 EDT Conifex Timber CFO Winny Tang resigns, Trevor Pruden to succeed - Conifex Timber announced the resignation of Ms. Winny Tang as CFO effective June 15, 2023 for personal reasons. Mr. Trevor Pruden will replace Ms. Tang as CFO effective the same date. Ms. Tang will focus on a smooth transition of her duties as Chief Financial Officer until her last day of employment in office. Pruden has been with Conifex since 2011 in various operational, finance and leadership roles. Prior to his current role, Mr. Pruden was Conifex's Vice President, Corporate Services and Strategic Planning. Mr. Pruden holds a Chartered Professional Accountant designation. . Tang is resigning for personal reasons, and not the result of other employment opportunities or disputes regarding Conifex's corporate strategy, financial statements or disclosures.

08:19 EDT Verses Technologies announces proceeds of $2.48M from warrant, option exercises - VERSES AI has received aggregate gross proceeds of $2,486,300 from the exercise of 189,130 broker warrants, 1,826,996 Class A subordinate voting share purchase warrants and 650,000 stock options. In connection with the foregoing exercises, the Company issued a total of 2,666,126 Class A subordinate voting shares.

08:16 EDT Xiao-I enters partnership with Chinadatapay for cognitive AI solutions - Xiao-I Corporation announced that it has entered into a strategic partnership with Guizhou Chinadatapay Network Technology to fuel Xiao-I's growth as a global leader in cognitive intelligence by combining Xiao-I's cognitive intelligence capabilities and Chinadatapay's big data expertise. This partnership aims for Xiao-I and Chinadatapay to demonstrate the power of integrating massive data sets with state-of-the-art algorithms and accelerate the advancement of industry-specific, big data-based large-scale models through intelligent data analysis, model training, and application development enabled by Xiao-I's cognitive intelligence technology and Chinadatapay's extensive data resources.

08:14 EDT Blue Water Vaccines announces corporate name change to Blue Water Biotech - Blue Water Vaccines announced that it has changed its corporate name to Blue Water Biotech. The corporate name change follows the Company's recent acquisition of ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia, BPH, which has commenced Blue Water's transition into a commercial-stage biotechnology company. "Our recent purchase of ENTADFI is transforming Blue Water into a commercial-stage biotechnology company and this name change is an exciting reflection of that progress," said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. "With ENTADFI, we are building a nimble and effective commercial operation that can be leveraged for our current pipeline or future acquired assets. Over the last few months, we have carefully developed a strong and experienced management team to lead us as we navigate this transition, and we are confident that the future of Blue Water and this product are very bright."

08:13 EDT Land & Buildings letter to Ventas notes significant NOI underperformance - Today Land & Buildings Investment Management (VTR) a significant shareholder of Ventas issued an open letter to the Ventas Board of Directors detailing Land & Buildings' continued dissatisfaction with the Company's long-term underperformance and undervaluation. Land & Buildings believes further action is necessary to address the lackluster returns shareholders have experienced under the current Board and intends to vote against the election of Lead Independent Director James Shelton and Board Chair Debra Cafaro at VTR's upcoming Annual Meeting of Shareholders. The letter said in part: "As we approach Ventas' Annual Meeting to be held on May 16, we are disappointed by the continued poor performance of the Company, especially against a backdrop of positive senior housing tailwinds. These positive indicators include: increasing demographic-driven needs-based demand, declining new competitive supply growth and waning expense headwinds. Shareholders had expressed their displeasure with several directors at the 2022 Annual Meeting, as Lead Independent Director James Shelton and Chair Debra Cafara received poor vote totals of 79% and 86%, respectively. When we first highlighted - over a year ago - the significant undervaluation and underperformance of Ventas and our suggestions for how to improve the Company VTR was trading at a 16% lower cash flow multiple and a 80bps higher implied cap rate to its closest peer Welltower (WELL). Both those spreads have now widened and are near all-time highs, with VTR trading at a 26% multiple discount to Welltower and 130bps higher cap rate."

08:12 EDT NewAmsterdam completes enrollment in Phase 3 BROOKLYN TRIAL - NewAmsterdam Pharma announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia, whose low-density lipoprotein cholesterol is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam expects to report topline results in the second half of 2024. The double-blind, placebo-controlled Phase 3 BROOKLYN trial enrolled 354 patients with a history of HeFH across ten countries in North America, Europe, and Africa. The mean baseline LDL-C for enrolled patients is greater than120 mg/dL despite high intensity statin use reported by approximately 70% of patients during screening. Females comprise approximately 53% of the study population and the median age of participants at baseline is 57 years. Patients were randomized to receive placebo or 10 mg obicetrapib dosed as a once-daily oral treatment with or without food for 52 weeks. The primary objective is to evaluate the effect of obicetrapib on LDL-C levels. Secondary objectives include evaluating the effect of obicetrapib on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein. The trial is also evaluating the safety and tolerability profile of obicetrapib.

08:10 EDT Global Crossing Airlines announces ddeliver of seventh A320 - Global Crossing Airlines Group announced it has taken delivery of its seventh passenger A320 on lease from Airborne Capital. The aircraft is a sistership to four ex-Alaska A320 aircraft currently operating at GlobalX, with a 12 business-138 economy seat configuration and installed Wi-Fi.

08:09 EDT Mullen's MAEO begins contract previously awarded to partner EV Technologies - Mullen Automotive (MULN) announces that its majority owned subsidiary, Mullen Advanced Energy Operations, MAEO, will begin execution of a $680,000 contract that was previously awarded by the District of Columbia, Washington, D.C., to EV Technologies (EVLV). The contract is for the purchase and installation of Energy Management Module units on Chevrolet Bolts within the D.C. city government's vehicle fleet. Mullen and EV Technologies' team of engineers are onsite in DC to commence installing the EMM units onto the Chevrolet Bolts and to perform the required tests included in the pilot. "The DC city project is the first of many that we have planned for the new EMM technology," said David Michery, CEO and chairman of Mullen Automotive, Inc. "Municipal city fleets are a perfect use case for EVs and even better with our Energy Management Modules added for extending vehicle range and performance. Ideally, the vehicles can spend less time charging and more time in the local communities for civic use and support."

08:07 EDT Harmony Biosciences names Jeffrey Dayno, M.D as CEO - Harmony Biosciences announced that Jeffrey Dayno, M.D., has been appointed President and CEO by the company's Board of Directors and has been elected to join as a member of the Board. Dayno joined Harmony as Chief Medical Officer and Executive Vice President when the company was founded in 2017 and has been serving as Interim President and CEO since January 6, 2023. With the appointment, Aronin returns to serving as non-executive Chairman of the Board.

08:05 EDT Zhongchao partners with public health foundation for cancer patient health - Zhongchao announced that Shanghai Zhongxin Medical, of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has entered into a service agreement with Beijing Public Health Foundation, a non-profit organization dedicated to enhancing Chinese citizens' health through public welfare initiatives and aid programs, to work together to develop a patient aid project. This Project will donate Trilaciclib Hydrochloride, which is used for protecting bone marrow during chemotherapy, to low-income cancer patients undergoing chemotherapy based on the patient's needs. It aims to provide drug aids for bone marrow protection to mitigate chemotherapy-related adverse reactions and improve the safety of chemotherapy. Zhongxin, leveraging its self-developed patient assistance program technical service platform, is responsible for developing the information system for the Project, verifying patients' medical and economic conditions, recruiting qualified patients, managing drug circulation, addressing patients' related questions, and providing other supports. Zhongchao believes that this cooperation and the Project will address chemotherapy-related bone marrow suppression for target patients and alleviate their financial burden.

08:05 EDT Future FinTech regains Nasdaq compliance - Future FinTech announced that on April 21, it received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the company has regained compliance with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1).

08:04 EDT Eyenovia announces poster presentation Optejet at ARVO 2023 - Eyenovia announced a poster presentation at the Association for Research in Vision and Ophthalmology 2023 annual meeting, which is being held April 23-27 in New Orleans. Summary: Treatment with the anti-glaucoma medication Latanoprost that is preserved with benzalkonium chloride over a long period of time has consistently demonstrated cytotoxic effects. This poster describes results of a study evaluating BAK-preserved latanoprost delivered via conventional eye dropper versus Eyenovia's proprietary Micro-Array Print technology. This study found that Optejet using MAP technology has the potential to reduce ocular surface stress when administering BAK+ latanoprost. Excellent human conjunctival cell tolerability was observed and was comparable to preservative-free latanoprost. Significantly less cell toxicity, significantly lower RNA levels of proinflammatory chemokine IL-6 and CCL2, and significantly lower protein levels of proinflammatory cytokine IL-6 were observed. Conclusion: MAP technology appears better in reducing inflammatory processes than BAK+ latanoprost administered with traditional eye drops. In conclusion, precision dosing has the potential to decrease ocular surface disorders typically associated with long-term use of preserved eye drops.

08:02 EDT Cerence announces enhancements to Cerence Car Knowledge - Cerence announced extensive enhancements to Cerence Car Knowledge that will leverage generative AI to deliver improved assistant intelligence and provide real-time information and support to drivers. With deep focus on the user experience and decades of expertise building in-car assistants, Cerence is uniquely positioned to use cutting-edge AI, large language models, and deep learning to create a more intelligent and natural interaction for drivers, bringing an ever-growing world of digital knowledge to the in-car assistant.

07:49 EDT MSP Recovery, Inc. receives notice of noncompliance from Nasdaq - MSP Recovery received a notification letter on April 18, 2023 from the Listing Qualifications Department of the Nasdaq Stock Market stating the Company was not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission. Under the Nasdaq rules, the Company has 60 calendar days, or until June 20, 2023, to file the 2022 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. This notification has no immediate effect on the listing of the Company's common stock on Nasdaq. However, if the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously disclosed, the Company is determined to restate its financial statements for the periods ended June 30, 2022 and September 30, 2022. Such restatements will be included in the 2022 Form 10-K, which the Company continues to work diligently to file as soon as possible. Such restatements relate to the reassessment of complex accounting matters based on non-cash adjustments and do not change the Company's strategy, daily operations, or mission to disrupt the antiquated healthcare reimbursement system with data-driven solutions for consumers and industries. The restatements do not affect the Company's cash position, nor do they reflect any financial distress. In addition, the Company has protocols in place for continued operations, including expected cash flows from recoveries as well as the previously announced equity purchase agreement, entered into on January 6, 2023, with a fund managed by Yorkville Advisors Global, LP, subject to the conditions set forth therein. Despite the current economic downturn affecting U.S. businesses, LifeWallet is confident in its financial future with advancements in blockchain technology that are expected to provide real-time revenue solutions, as well as ongoing recovery efforts that seek reimbursements on behalf of LifeWallet's Medicare and Medicaid clients, from responsible parties. A substantial volume of cases are being litigated. As is the norm in the judicial system, revenue is reported once cases reach a settlement or judgment, and LifeWallet continues to strive towards positive outcomes for its healthcare clients and investors.

07:39 EDT Ameresco ,Sunel team to bid EPC PV solar and BESS projects exceeding 1,5 GWp - Ameresco and Sunel Group, an international developer and EPC contractor for energy projects, have joined forces to bid projects exceeding 1,5 GWp in the United Kingdom, Greece, Italy, Spain and Romania. Ameresco, Inc. and Sunel Group have established Ameresco Sunel Energy S.A., which has already been selected by Cero Generation, a leading European solar energy developer, as the contractor for "Delfini", a 100MWp solar photovoltaic project in Greece, currently in the construction phase. The 1,5 GWp of new projects that are currently in the bidding phase are expected to exceed $500M USD in contract value. The partnership combines Ameresco and Sunel's extensive experience in engineering, procurement, construction, operation and maintenance of large scale photovoltaic and battery energy storage projects. Together, they aim to offer comprehensive solutions that will generate added value to project investors. The projects that will be constructed will make a significant contribution to reducing carbon emissions and increasing the share of renewable energy across Europe's electricity grid. The solar component of these projects will generate clean electricity while the battery energy storage systems will provide grid stabilization services to improve the reliability and resilience of the grid.

07:37 EDT Bluebird Bio submits BLA for lovo-cel gene therapy for SCD treatments - bluebird bio announced the submission of its Biologics License Application, BLA ,to the U.S. Food and Drug Administration, FDA ,for lovotibeglogene autotemcel or lovo-cel gene therapy in patients with sickle cell disease SCD ages 12 and older who have a history of vaso-occlusive events. The BLA includes a request for Priority Review, which, if granted, would shorten the FDA's review of the application to six months from the time of filing, versus a standard review timeline of 10 months. If approved, lovo-cel will be bluebird bio's third ex-vivo gene therapy approved by the FDA for a rare genetic disease and its second FDA approval for an inherited hemoglobin disorder, building on more than a decade of leadership in gene therapy. "The severity of sickle cell disease, and its impact on patients and caregivers, has been underappreciated and overlooked for far too long. Transformative therapies for this community are long overdue," said Andrew Obenshain, chief executive officer, bluebird bio. "We are pleased to have satisfied the Agency's questions about comparability to enable our BLA submission, and to take this important step toward making lovo-cel available for individuals living with SCD." The FDA previously granted lovo-cel orphan drug designation, fast track designation, regenerative medicine advanced therapy designation, and rare pediatric disease designation for the treatment of SCD.

07:35 EDT Casella to acquire certain operations in PA, DE, MD from GFL Environmental - Casella Waste Systems (CWST) announced the signing of an equity purchase agreement on April 21, 2023, to acquire collection, transfer, and recycling operations in Pennsylvania, PA, Delaware, DE, and Maryland, MD, from GFL Environmental (GFL) for a purchase price of $525 million. The proposed acquisition includes nine hauling operations, one transfer station, and one material recovery facility with aggregate annualized revenues of approximately $185 million. The acquisition is expected to close by the third quarter of 2023, subject to customary closing conditions, including regulatory approvals. "Today's announcement marks an important step forward in the company's growth strategy by using the strength of our balance sheet and proven capital discipline to make a compelling investment," said John W. Casella, Chairman and CEO of Casella Waste Systems, Inc. "After successfully extending our footprint into the adjacent Connecticut market with an acquisition in mid-2021, this acquisition will enable us to expand into the Mid-Atlantic region with these well-run solid waste operations that provide a platform for future growth." The acquisition is not subject to any financing conditions and Casella expects to fund the purchase price through a combination of cash on hand, revolving credit facility borrowings, and from a planned new Term Loan A under its existing senior secured credit facility. The acquisition was unanimously approved by Casella's Board of Directors and is expected to close by the third quarter of 2023, subject to customary closing conditions, including regulatory approvals.

07:33 EDT Lantheus, Point Biopharma announces FDA grants FTD for 177Lu-PNT2002 - Lantheus (LNTH) and POINT Biopharma Global (PNT) announced the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer. "Fast track designation by the FDA is an important milestone and recognizes the potential for 177Lu-PNT2002 to address the significant unmet need for mCRPC patients," said Jean-Claude Provost, M.D., Chief Medical Officer at Lantheus. "We are encouraged by the FDA's decision as it reflects the need for FDA approved and widely available treatments for these patients. This designation will allow us to work closely with the FDA, along with our partner POINT, to quickly advance 177Lu-PNT2002, with the potential to make a meaningful difference for patients who require new treatment options."

07:32 EDT Soligenix requests Type A meeting with FDA for Phase 3 HyBryte study in lymphoma - Soligenix has submitted a Type A Meeting Request to the FDA to initiate formal discussions regarding the design of a second, Phase 3 pivotal study evaluating HyBryte in the treatment of early stage cutaneous T-cell lymphoma, a rare cancer, where it has successfully demonstrated statistically significant results in the first Phase 3 clinical trial. The Type A Meeting is the highest priority classification of meeting the FDA grants and is expected to occur approximately 30 days from the FDA's receipt of the meeting request.

07:17 EDT Krystal Biotech announces data on topical application of B-VEC - Krystal Biotech announced that the Company presented new data on the compassionate use of topical beremagene geperpavec, B-VEC, to treat a patient with dystrophic epidermolysis bullosa, DEB, with recurrent cicatrizing conjunctivitis at the Association for Research in Vision and Ophthalmology, ARVO, 2023 Annual Meeting on April 23, 2023. The data presented describes the first application of B-VEC to treat ocular complications in a patient with DEB under a compassionate use program. B-VEC was well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to 20/40 at 7 months, the latest time point of the on-going treatment effect evaluation. No drug-related adverse events have been observed. Two non drug related, serious AEs were reported: 1) Prolonged hospitalization due to complications post-gastrointestinal surgery, and 2) Prolonged hospitalization due to complications post-esophageal dilation. B-VEC treatment was not interrupted during either event. Ocular complications are common in patients with DEB, with over half of the patients diagnosed with recessive DEB potentially affected. Typical ocular manifestations include corneal abrasion, as well as corneal scarring, pannus, eyelid ectropions and blisters.1,2 There are no specific FDA-approved treatment options for ocular manifestations of DEB.3

07:15 EDT Aclarion announces publication of two-year durability data in DLBP surgeries - Aclarion announced the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain surgeries at chemically painful lumbar discs identified by Nociscan. The multi-year, single site clinical trial comprised 78 patients who received surgery for DLBP following standard clinical work-up including MRI and provocative discography. Nociscan was performed on all patients but was not available in the surgical decision-making process. The patient outcomes were evaluated using the Oswestry Disability Index scoring scale, a common clinical outcomes measure for low back pain, where surgical success was defined using an industry-standard improvement of 15 points or more between surgeries that were concordant versus discordant with Nociscan results. Surgical success rates at 2 years illustrates a 22 percentage point improvement between the two groups. The results suggest that Nociscan provides valuable new information that can help physicians successfully treat DLBP.

07:13 EDT Aslan Pharmaceuticals announces four abstracts at ISID meeting - ASLAN Pharmaceuticals announced the acceptance of two late-breaker abstracts - one on eblasakimab and one on farudodstat - for presentation at the 1st International Societies for Investigative Dermatology, ISID, Meeting. Late-breaker presentations: Late-breaker oral presentation: Downstream effects of IL-13alpha1 blockade on Type 2 inflammation and Th1 immune axis activation in atopic dermatitis, Late-breaker poster presentation: A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment. 2023 ISID published abstracts - Abstract 1: Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study. The clinical presentation of AD varies by anatomical location due to differences in skin area sensitivity and can limit an individual's long-term treatment options. Current research shows that interleukin-4 and IL-13 signal through a Type 2 receptor complex composed of IL-4Ralpha1 and IL-13Ralpha1 to mediate the pathogenesis of AD. Eblasakimab obstructs this signaling cascade by binding to the IL-13Ralpha1 subunit. The Phase 1b subgroup analysis explored the effects of eblasakimab on Eczema Area and Severity Index across different anatomical regions compared to placebo. Abstract 2: Neuromodulation beyond itch is blocked by targeting IL-13Ralpha1 with eblasakimab. IL-4 and IL-13, two cytokines that play a pivotal role in the pathogenesis of AD, are associated with high-burden symptoms such as chronic itch. This study evaluated 1) whether IL-4 and IL-13 exert redundant or distinct functions in human sensory neurons, and whether eblasakimab can 2) attenuate cytokine-enhanced neuronal responses to itch and 3) reduce spontaneous neuronal activity. Human dorsal root ganglia neurons were treated with IL-4, IL-13, or their combination with or without eblasakimab and subsequently either challenged with pruritogens or tested for spontaneous neuronal activity. When applied to human dorsal root ganglion, IL-4, IL-13, and their combination treatments enhanced neuronal responses to the non-histaminergic pruritogen and IL-13 treatment increased neuronal responses to the histaminergic pruritogen through amplifications of the activity of MRGPRX2. Eblasakimab significantly hampered cytokine-enhanced itch responses to both pruritogens.These results reveal that IL-4 and IL-13 exert nonredundant neuronal function and demonstrate the ability of eblasakimab to block these effects. This indicates that direct impact on neuronal responses may contribute to reduction of chronic itch demonstrated in AD patients treated with eblasakimab.

07:12 EDT Extreme Networks appoints Kevin Rhodes as CFO - Extreme Networks (EXTR) announced it has appointed Kevin Rhodes as executive VP and CFO, effective May 30. Rhodes will help drive the company's strategic direction, financial planning and reporting with a focus on developing and implementing key initiatives that support Extreme's continued growth and expansion. Prior to Extreme, Rhodes was EVP and CFO at Duck Creek Technologies (DCT).

07:09 EDT BioRestorative completes enrollment for safety run-in of Phase 2 BRTX-100 study - BioRestorative Therapies announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease. BRTX-100 is the Company's lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial to treat cLDD. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug or control in a 2:1 fashion.

07:08 EDT Kaixin Auto announces development of AIGC system 'Happy Buy Car' - Kaixin Auto announces that it has formed a specialized technical team to develop its AIGC system "Happy Buy Car." Kaixin has been dedicated to developing the intelligent "Happy Buy Car" system in the past. The newly formed technical team will conduct in-depth research on AIGC and ChatGPT-related technological applications and expedite development of the "Happy Buy Car" system. The system will be equipped with such features as interactive "real person" dialogues and highly relevant text and video content generation for automobile sales, that will enhance the richness of marketing and sales content and empower its dealerships to increase sales conversion rates.

07:07 EDT Coca-Cola reports Q1 cash flow from operations $160M, down $460M y/y - Cash flow from operations was $160M, a decline of approximately $460M versus the prior year, largely due to the timing of working capital initiatives and payments related to acquisitions and divestitures. Free cash flow (non-GAAP) declined approximately $520M versus the prior year, resulting in negative free cash flow of approximately $120M.

07:07 EDT Can-Fite appoints Farbstein CEO, Dr. Fishman appointed executive chairman - Can-Fite BioPharma announced executive changes to support the Company's continued success in advancing its pipeline toward commercialization through two pivotal Phase III trials in psoriasis and liver cancer. Dr. Pnina Fishman, the Company's Scientific Founder, was appointed Executive Chairman of the Board to guide the Company's strategic direction. She will continue to serve as Chief Scientific Officer CSO overseeing the Company's scientific programs and clinical development pipeline. Motti Farbstein will lead the Company as its new Chief Executive Office CEO while continuing to serve as the Company's Chief Financial Officer CFO , a position he has held since 2005. Dr. Ilan Cohn, the Company's Co-Founder and former Chairman, remains on the Board and will continue to guide the Company's intellectual property strategy and portfolio. Dr. Cohn is a patent attorney and a Co-Founder and Senior Partner of the IP firm Cohn, De Vries, Stadler & Co. These executive changes go into effect on June 30, 2023. "Having developed Can-Fite's platform technology and guided our pipeline into pivotal studies, I am pleased to turn the CEO role over to Motti who has the financial and clinical expertise to lead Can-Fite into the registration stage," Dr. Fishman stated. "I will continue to guide our clinical programs as CSO while also taking part in setting the Company's strategic direction as Executive Chairman of the Board.

07:06 EDT Applied announces benefits of govorestat in ACTION-Galactosemia kids trial - Applied Therapeutics announced results from the ACTION-Galactosemia Kids study of govorestat, AT-007, a novel, oral, small molecule, central nervous system penetrant Aldose Reductase inhibitor. "We believe Govorestat has demonstrated compelling evidence of clinical benefit alongside a favorable safety profile in patients with Galactosemia," said Shoshana Shendelman, PhD, CEO, Founder and Chair of the Board of Applied Therapeutics. "We look forward to working collaboratively with regulators to ensure that this important treatment is available to patients with Galactosemia as quickly as possible. We plan to request a pre-NDA meeting with the FDA, and we have already received feedback from the EMA supportive of a submission in Europe." The ACTION-Galactosemia Kids Phase 3 study was designed to evaluate the impact of govorestat treatment vs. placebo on clinical outcomes over time in 47 children age 2-17 with Galactosemia. The primary endpoint, the Global Statistical Test, was a composite sum of change comprised of four endpoints: OWLS-2 Oral Expression, OWLS-2 Listening Comprehension, BASC-3 Behavior Symptoms Index and the BASC-3 Activities of Daily Living. An additional pre-specified sensitivity analysis included cognition in the primary endpoint. Additional clinical outcomes were assessed as secondary endpoints, including adaptive skills and tremor. Clinical outcomes were assessed every 6 months by a firewalled independent Data Monitoring Committee.

07:05 EDT Ginkgo Bioworks and Visolis partner to improve bio-isoprene for aviation fuel - Ginkgo Bioworks announced a partnership with Visolis, a company combining bioengineering with chemical catalysis to provide sustainable, carbon-negative materials. Visolis aims to leverage Ginkgo's extensive capabilities in strain engineering to improve upon an existing microbial strain for the commercial production of a key feedstock ingredient used to make bio-based isoprene and sustainable aviation fuels. Achieving the production of bio-based isoprene at scale represents a significant step toward decarbonizing tire manufacturing. Isoprene can also be used as an intermediate for high performance, lower carbon intensity sustainable aviation fuel production. Through the partnership with Ginkgo, the two companies are working to further optimize the efficiency of this biomanufacturing process.

07:04 EDT Phoenix Motor promotes Dr. Lee and adds Dr. Joseph Xiang to senior managemt - Phoenix Motor is pleased to announce the promotion of Dr. Frank Lee to Chief Technology Officer and the hiring of Dr. Joseph Xiang to serve as Vice President of Electrical and Software Engineering. "We are proud to be able to attract such talented, seasoned industry veterans," said Dr. Lance Zhou, CEO of Phoenix Motorcars. "The promotion of Frank and the addition of Joseph to our senior management team further positions Phoenix for success as we continue to execute on our global growth strategy." Chris Wang, CFO of Phoenix Motorcars, commented, "The promotion of Frank and addition of Joseph lends additional knowledge and expertise to our operational and technical capabilities. I am proud of the team we have built and our successes to date. Phoenix is poised for transformational growth within the rapidly developing medium-duty EV market." Dr. Frank Lee brings over 30 years of experience in vehicle development, with expertise in auto body structure, power train integration and vehicle integration, as well as vehicle product strategy and product development systems. Dr. Lee joined Phoenix last year and prior to that had most recently served as Vice President of Vehicle Integration at Karma Automotive, an Irvine, CA-based EV manufacturer. Previously Dr. Lee has held senior leadership positions including Chief Engineer for BYD Auto, Deputy General Manager for Beiben Trucks, and VP/Senior Chief Engineer for Geely Holding Group. Dr. Lee earned his Ph.D. in Engineering Mechanics from Ohio State University, in Columbus, Ohio, and his MA in Mechanics and BS in Mechanics from the Huazhong University of Science and Technology. Dr. Joseph Xiang brings 35 years of engineering experience, with more than 25 years in the automotive arena. Dr. Xiang most recently served as a Staff Motor Control Engineer for SERES, previously serving for twelve years as General Manager of Corporate Engineering for Johnson Electric International Ltd., in Hong Kong. Prior to this Dr. Xiang worked in Dearborn, MI, for Visteon Corp for seven years and Ford for five years, in senior leadership roles including as an Electric Drive and Control Technical Expert, as a Technical Professional and Product Design Engineer. Dr. Xiang earned his Ph.D. in Electrical Engineering from the University of Kentucky, and his MSEE and BSEE degrees from the Huazhong University of Science and Technology in Wuhan, China.

07:03 EDT Palanti to support Ukrainian Prosecutor-General's war crimes investigation - Palantir has announced a landmark agreement with the Prosecutor General's Office of Ukraine which will enable investigators on the ground and across Europe to share, integrate, and process all key data relating to more than 78,000 registered war crimes. The OPG's war crimes register documents all recorded incidents of war crimes relating to the armed conflict in Ukraine. The software will enable: integration of open-source intelligence and satellite imagery to construct a virtual map of war crimes evidence; cataloguing by prosecutors of the vast quantity of data to support workflows for removing data duplication, helping establish source reliability, and identifying potential links across different sources of data in order to speed up the path to building compelling cases; establishing attribution by providing prosecutors with the tools for building a clear picture of the chain of command for Russian forces in Ukraine, while mapping Russian military units to criminal activity; Ukrainian and international partners to securely and legally collate and share otherwise siloed information. It will also help to ensure chain of custody.

06:59 EDT Aecom-led joint venture selected for Pure Water Southern California support - Aecom's Aecom-BC Team joint venture with Brown and Caldwell has been selected by the Metropolitan Water District of Southern California to provide program management support services for the Pure Water Southern California program. An initiative of Metropolitan and the Los Angeles County Sanitation Districts, the program will create a sustainable new water supply for Southern California by purifying cleaned wastewater. The Aecom-BC joint venture will provide a comprehensive suite of services, including program and project management support; program administration, controls, and reporting; engineering; design; quality assurance and control; and risk assessment and management. With potential for water delivery as early as 2028, Pure Water Southern California is expected to produce up to 150 million gallons of water daily.

06:48 EDT Eli Lilly to divest Baqsimi to Amphastar for $500M upfront - Eli Lilly (LLY) and Amphastar (AMPH) have entered into a definitive agreement for Lilly to divest Baqsimi worldwide to Amphastar. Amphastar expects to provide dedicated commercial investment for Baqsimi. Pursuant to the terms of the agreement, Amphastar will pay Lilly $500M in cash at closing and an additional $125M in cash upon the one-year anniversary of closing. Lilly is also eligible to receive sales-based milestone payments of up to $450M in aggregate. The transaction has been approved by the boards of directors of both companies. The transaction is not subject to any financing conditions and is expected to close in the second or third quarter of 2023, subject to the satisfaction of customary closing conditions. Each of Lilly and Amphastar will determine their applicable accounting treatment for this transaction according to GAAP upon closing. This transaction will thereafter be reflected in each company's respective financial results and financial guidance.

06:45 EDT Senstar Technologies appoints Fabien Haubert as interim CEO - Senstar Technologies announced that its board of directors has appointed Fabien Haubert as interim CEO of the company effective April 21. This appointment follows Dror Sharon's decision to retire from his role as the company's CEO. Haubert joined Senstar in 2018 as VP, sales EMEA.

06:33 EDT Design Therapeutics' DT-168 molecule shows efficacy in corneal dystrophy - Design Therapeutics announced that preclinical data for the company's novel GeneTAC small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy, will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting in New Orleans from April 23-27. FECD is characterized by progressive corneal degeneration leading to vision loss and affects millions of people in the U.S. There are no disease-modifying therapies approved for FECD, and advanced cases generally require ocular surgery, including corneal transplant. DT-168 is designed to selectively target the expanded CTG repeats in the TCF4 gene to reduce RNA foci formation and mis-splicing. In preclinical studies, DT-168 reduced foci in patient-derived primary corneal endothelial cells to levels seen in cells from healthy individuals with low nanomolar IC50 values. Treatment with DT-168 also significantly improved mis-splicing in patient-derived CECs across a panel of genes. Additionally, in animal studies DT-168 eye drops were well-tolerated after multiple doses and distributed throughout the cornea with micromolar levels of DT-168 observed in the cornea 24 hours after dosing. Design remains on-track to submit an Investigational New Drug application for DT-168 for the treatment of FECD in the second half of 2023.

06:17 EDT Sagaliam Acquisition extends business combination deadline - Sagaliam Acquisition is exercising its option to extend the time available to consummate its business combination to May 23. On March 23, GLD Sponsor Member, a Delaware limited liability company, entered into a Membership Interest Purchase Agreement with BN Holdings Trust, a Nevada Trust and Sagaliam Sponsor, pursuant to which BN Holdings Trust agreed to purchase all of the issued and outstanding equity interests in the sponsor from the seller, which constitutes 100% of the membership interests in the sponsor. The consummation of the transactions contemplated by the purchase Agreement is expected to take place on or before April 28. The date by which the company has to complete its business combination has been extended by the company from April 23 to May 23 by depositing $57,380.22 into the trust account for its public stockholders. The extension is the fifth of ten one-month extensions permitted under the company's governing documents and provides the company with additional time to complete its business combination.

06:04 EDT Waste Connections CEO Worthing Jackman departs, Ronald Mittelstaedt succeeds - Waste Connections announced that Ronald Mittelstaedt, the executive chairman of the company, has been appointed president and CEO of the company, effective April 23. Mittelstaedt succeeds Worthing Jackman in this role. Upon his departure, Jackman also stepped down as a member of the company's board of directors and withdrew as a nominee for election as a director at the Company's 2023 Annual Meeting of Shareholders.

05:16 EDT Thermo Fisher, Devyser Diagnostics enter NGS products distribution agreement - Devyser Diagnostics announced that the company has signed an exclusive collaboration and distribution agreement with Thermo Fisher. The agreement gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser's post-transplant portfolio of NGS products in North America and Europe. The collaboration and distribution agreement signed today gives Thermo Fisher exclusive rights to market and sell, under combined brands, Devyser's post-transplant portfolio in North America and Europe. Devyser retains the rights to commercialize its post-transplant products in US via its own service laboratory, as a service to US laboratories. Devyser will continue to manufacture all products under the agreement.

05:08 EDT InterDigital appoints Skip Maloney as chief people officer - InterDigital (IDCC) announced that Skip Maloney has been appointed as the company's new chief people officer, reporting to Liren Chen, president and CEO of InterDigital. Skip has over 25 years of industry experience and joins InterDigital from Aspen Technology (AZPN), where he served as the chief human resource officer since 2018.